Report: Black Friday Cannabis Spending increased 20%, while Overall Retail decreased 28.3%

3.1 min readPublished On: December 2nd, 2021By

DENVER – Business intelligence from Akerna (Nasdaq: KERN), an enterprise software company and the developer of comprehensive technology infrastructure, ecosystem, and compliance engine for the global cannabis industry, shows that Green Wednesday (11/24) and Black Friday (11/26) were the second and third highest sales days for legal cannabis in the US this year, with Green Wednesday bringing in $98.2 million in sales and Black Friday bringing in another $99 million. The day for cannabis sales this year was 4/20, the unofficial cannabis consumption holiday.

A report released by Sensormatic this week revealed that overall retail traffic on Black Friday dropped 28.3% compared to 2019 levels, while Akerna data shows a 20% increase in cannabis industry Black Friday purchasing over the same time period. 2020 was omitted from the comparison due to low in-store presence amid the first year of the Covid pandemic.

“Green Wednesday earned its nickname from historically high cannabis sales, and this year proved the same,” said James Ahrendt, Business Intelligence Architect at Akerna. “Cannabis shoppers headed to dispensaries in droves on both Black Friday and Green Wednesday, bucking national mainstream retail trends.”

The four-day period surrounding the Thanksgiving holiday (11/24-11/27) brought in a total of $254.7 million in cannabis sales. Akerna released a prediction report last week estimating the time period would garner $251 million in sales, which was 98.5% accurate compared to the actual total sales.

Other values for 11/24 – 11/27:

  1. Category sales:
         a.       Flower – 47%
         b.      Cartridge/Pens – 33.5%
         c.       Concentrates – 11%
         d.      Infused Edibles – 7%
         e.      Other – 1.5%
  2. Average order total:
         a.       Medical – $122.76
         b.      Recreational – $79.37
  3. Average products per purchase:
         a.       Medical – 3.31
         b.      Recreational – 3.17
  4. Sales by demographic:
         a.       61.8% male
         b.      38.2% female sales
  5. Sales by age group:
         a.       Under 30 – 29%
         b.      30-40 –31%
         c.       40-50 – 20%
         d.      50-60 –12%
         e.      Over 60 – 8%

Forward-Looking Statements:

Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such terms or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding the ability of the MJ Platform team to help operators make decisions through analytics and reporting. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include (i) Akerna’s ability to maintain relationships with customers and suppliers and retain its management and key employees, (ii) changes in applicable laws or regulations, (iii) changes in the market place due to the coronavirus pandemic or other market factors, (iv) and other risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under “Risk Factors” therein. You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources believed to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

(This information is primarily sourced from Akerna.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

ACS Laboratory Announces New THCOa Safety Bundle

January 19th, 2022|

BOCA RATON, Fla. - ACS Laboratory, hemp and cannabis testing facility in the eastern U.S., has developed the THCOa Safety Bundle Test, a testing panel to test for THC-O Acetate (THCOa), acetic anhydride and other ...

Curaleaf Completes Acquisition of Bloom Dispensaries

January 19th, 2022|

WAKEFIELD, Mass. - Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF), an international provider of consumer products in cannabis, announced the completion of its previously announced acquisition of Bloom Dispensaries, a single state cannabis operator ...